Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-12,275
Closed -$2.03M 106
2020
Q4
$2.03M Sell
12,275
-14,285
-54% -$2.32M 1.07% 37
2020
Q3
$4.39M Sell
26,560
-1,410
-5% -$217K 2.69% 12
2020
Q2
$3.83M Buy
27,970
+1,060
+4% +$138K 2.69% 11
2020
Q1
$3.17M Sell
26,910
-1,850
-6% -$244K 4.5% 6
2019
Q4
$3.81M Sell
28,760
-606
-2% -$75.3K 2.63% 15
2019
Q3
$3.66M Sell
29,366
-7,299
-20% -$881K 2.85% 12
2019
Q2
$4.16M Buy
36,665
+3,275
+10% +$343K 3.36% 8
2019
Q1
$3.36M Buy
33,390
+16,720
+100% +$1.52M 2.87% 13
2018
Q4
$1.43M Sell
16,670
-765
-4% -$68.9K 1.65% 26
2018
Q3
$1.6M Buy
17,435
+5,020
+40% +$445K 1.23% 29
2018
Q2
$1.06M Buy
+12,415
New +$1.05M 0.84% 41

Other funds holding ZTS

Geneva Partners's ZTS Position: Q1 2021 in Review

Geneva Partners sold out of Zoetis (ZTS) in Q1 2021, closing a stake of 12,275 shares — an estimated $2.03M sold.

Geneva Partners first reported a position in ZTS in Q2 2018 and held it in 11 quarters. The position peaked at $4.39M in Q3 2020. 1,415 funds tracked by Wall St. Rank hold ZTS as of Q1 2021.

  • Geneva Partners reported no remaining Zoetis position as of Q1 2021 after selling out during the quarter.
  • Geneva Partners sold 12,275 Zoetis shares in Q1 2021, an estimated $2.03M.
  • Geneva Partners first reported a position in Zoetis in Q2 2018 and held it in 11 quarters.
  • Geneva Partners's Zoetis position peaked at $4.39M in Q3 2020.
  • 1,415 funds tracked by Wall St. Rank held Zoetis as of Q1 2021.

Based on Geneva Partners's 13F filing for Q1 2021, filed 5 May 2021.